Jorges E. Cortes, MD, deputy chair of the department of leukemia in the division of cancer medicine at the University of Texas MD Anderson Cancer Center, discusses where quizartinib would fit into the treatment landscape for patients with acute myeloid leukemia (AML).
Based on the data from the QuANTUM-R trial, quizartinib could be a possible treatment option for patients with relapsed/refractory AML in the salvage setting. This is similar to FDA-approved gilteritinib, Cortes says.
Both of these agents are not only oral and well-tolerated, but they are very effective in this patient population. The population seen in the QuANTUM-R trial is a bit more difficult to treat, according to Cortes, but oncologists can be confident in their use of either of these 2 agents.
For more resources and information regarding anticancer targeted therapies in AML: [ Ссылка ]
